Cytochrome P450 3A (CYP3A) enzymes are involved in the metabolism of over half of today's prescription drugs. As a result, drugs metabolized by CYP3A have a risk of drug–drug interactions (DDIs). Recent studies have shown the potential to use 4β-hydroxycholesterol as an endogenous biomarker of CYP3A activity and predictor of potential DDIs. Bristol–Myers Squibb has developed a liquid chromatography-electron ionization-tandem mass spectrometry method that accurately measures 4β-hydroxycholesterol levels in clinical plasma samples following treatment with a CYP3A inducer or inhibitor. Stable isotope labeled (SIL) [D4]- and [D7]-4β-hydroxycholesterols were synthesized to assist in the development of this new quantification method. The SIL analogs were prepared from the appropriate [D4]- or [D7]-cholesterol starting material in two steps. The labeled cholesterols were oxidized with bromine and silver acetate in pyridine to give an acetate protected hydroxy group at C4. Hydrolysis of the acetate protecting group provided [D4]- and [D7]-4β-hydroxycholesterols in 15%–28% overall yield. 4α-Hydroxycholesterol was also required during method development and was prepared in four steps from cholesteryl benzoate in 1% overall yield.
细胞色素 P450 3A (CYP3A) 酶参与了当今一半以上处方药的代谢。因此,经 CYP3A 代谢的药物有发生药物间相互作用 (DDI) 的风险。最近的研究表明,4β-羟基
胆固醇有可能被用作 CYP3A 活性的内源性
生物标记物和潜在 DDIs 的预测因子。百时美施贵宝公司已开发出一种
液相色谱-电离-串联质谱方法,可准确测量临床血浆样本中使用 CYP3A 诱导剂或
抑制剂治疗后的 4β- 羟基
胆固醇水平。为了帮助开发这种新的定量方法,我们合成了稳定同位素标记(SIL)[
D4]- 和 [D7]-4β-羟基
胆固醇。SIL 类似物由适当的[
D4]-或[D7]-
胆固醇起始材料分两步制备而成。标记的
胆固醇在
吡啶中被
溴和
乙酸银氧化,从而在 C4 处产生一个受
乙酸酯保护的羟基。
水解
乙酸酯保护基团可得到[
D4]-和[D7]-4β-羟基
胆固醇,总产率为 15%-28%。4α- 羟基
胆固醇也是在方法开发过程中需要的,由
胆固醇苯甲酸酯分四步制备,总收率为 1%。